USAMMDA

U. S. Army Medical Materiel Development Activity

USAMRMC

USAMMDA MISSION is to develop and manage medical materiel to protect and sustain the Warfighter on point for the Nation.

Adenovirus Vaccine

The adenovirus vaccine (Adenovirus Type 4 and Type 7 Vaccine, Live, Oral) is used by the Department of Defense to prevent adenovirus-related acute respiratory disease in military recruits during basic training. Since the adenovirus can be spread via direct contact, airborne transmission and droplet transmission, the close quarters of recruit life make trainees highly susceptible to exposure.

Adenovirus infections in military recruits are associated with pharyngitis, conjunctivitis, rhinitis and pneumonia. These illnesses often lead to missed training and some recruits have to repeat parts of the training cycle.

The adenovirus vaccine is two orally administered, enteric-coated tablets containing live adenovirus serotypes 4 or 7.

Each initial-entry recruit will receive a one-time dose of both serotypes, along with their other immunizations, during in-processing.



Timeline

- 1996: Vaccine production ceased due to loss of manufacturer
- 1999: Stocks were depleted or expired

  Several adenovirus outbreaks have recurred since 1999

  Adenovirus type 4 returned as a major cause of febrile acute respiratory disease in basic trainees.
- 2001: Contract to develop and manufacture adenovirus vaccine awarded to Barr Pharmaceuticals
- 2004: Barr Pharmaceuticals submitted the Investigational New Drug (IND) application to the FDA
- 2004-2005: Phase 1 clinical trial
- 2006-2008: Phase 3 clinical trial

  Clinical studies were carried out jointly by the Army and Navy
- 2008: Biological License Application (BLA) submitted to the FDA
- 2011: FDA approved the BLA ; Barr Labs, Inc. and DoD initiate distribution

USAMMDA Contact
Product Manager
301.619.4821

Development Partners
USAMMDA
WRAIR
NHRC